Reviva pharmaceuticals announces presentation of clinical pharmacology studies data on brilaroxazine at the aspet 2023 annual meeting

Data reinforce brilaroxazine's differentiated clinical pharmacology and safety profile brilaroxazine may be co-administered with other drugs metabolized by cyp3a inhibitors metabolism and excretion profiles of brilaroxazine were similar across mice, canines, and humans cupertino, calif., may 22, 2023 (globe newswire) -- reviva pharmaceuticals holdings, inc. (nasdaq: rvph) (“reviva” or the “company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (cns), respiratory and metabolic diseases, has presented two posters on promising clinical pharmacology and safety studies data on the novel serotonin-dopamine stabilizer brilaroxazine at the american society for pharmacology and experimental therapeutics (aspet) 2023 annual meeting took place in st. louis, missouri, usa, may 18-21, 2023.
RVPH Ratings Summary
RVPH Quant Ranking